In vitro diagnostic medical devices for the exclusive use of healthcare professionals.

DiagnoLung®

What is DiagnoLung®?

It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT).

AMADIX Test de cáncer de pulmón
consulta medico pulmones

How does it work?

DiagnoLung® identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung Cancer

  • Biomarker signature.
  • Non-invasive test in blood.
  • Easy, low cost and a common technique for hospitals and laboratories.
  • Confirmation of lung cancer and risk assessment of Incidental Pulmonary Nodules (IPNs) in positive Low Dose Computed Tomography (LDCT) patients and that are incidentally detected.

DiagnoLung® characteristics

Learn more about DiagnoLung®

DiagnoLung is intended for:

  1. The risk assessment for malignancy of Incidental pulmonary nodules (IPNs):
    • Incidentally detected
    • Positive Low Dose Computed Tomography patients, improving the performance of the Low Dose Computed Tomography screening program
  2. The confirmation of lung cancer in inconclusive diagnostics. 

In patients with indeterminate pulmonary nodules, between 6 and 30 mm, DiagnoLung would allow physicians to identify patients with likely benign nodules who would become candidates for serial Computed Tomography (CT) monitoring within 2 years.

In a screening context, DiagnoLung is indicated to confirm positive Low Dose Computed Tomography (LDCT) results that may indicate the presence of lung cancer and should be confirmed with an invasive test (biopsies). 

Performed in conjunction with a biopsy, DiagnoLung can be used to confirm cancer in patients with inconclusive cytological and histological analysis (in a clinical context, it is not possible to confirm the diagnosis in up to 50% of first bronchoscopies).

It is not a replacement for diagnostic methods or the monitoring of high-risk individuals (50 to 80 years old and in fairly good health, who currently smoke or who have quit in the past 15 years and have at least a 20 pack/year smoking history).

Diagnolung

Revolutionary science

Rigorous protection

Duly protected internationally through two family patents.

*Pending patent in Canada.

Glossary

All about Cancer

Lung Cancer

Lung cancer is one of the most important health problems worldwide and the leading cause of deaths from cancer (1.79M in 2020). More than 2 million lung cancers are diagnosed every year.  The incidence of lung cancer in Spain in 2020 was 63.4 cases per 100,000 inhabitants (29,188 total cases).

La incidencia de cáncer de pulmón continúa creciendo se estiman 3,25 millones de nuevos casos en todo el mundo para 2035 (…)
Read more

Prevention

In medicine, prevention is the measures taken to reduce the chances of developing an illness, like getting vaccinated. In cancer, prevention is the best way to reduce the chances of having cancer, and if you have it, it is the best way to detect it in its early stages, thus leading to a higher survival rate.

Hay diferentes niveles de prevención (…)
Read more

Screening

Early detection, through screening programs, is essential for cancer control. Screening programs consist of carrying out diagnostic tests on people who are initially healthy. For some time now, early detection of lung cancer with low-dose computerized tomography (LDCT) has been proving to be effective in reducing mortality in specific high-risk groups.

Aunque la mortalidad está disminuyendo para la mayoría de los cánceres, el cáncer de pulmón continúa aumentando en todo el mundo, especialmente entre las mujeres. (…)
Read more

PancreaDix®

What is PancreaDix®?

PancreaDix® is an innovative, non-invasive signature in blood for:

  • Confirming a Pancreatic cancer diagnosis
  • Detecting pre-malignant lesions that will evolve to cancer
  • Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors.
  •  
AMADIX Test de cáncer de páncreas
tubo de ensayo

How does it work?

PancreaDix® identifies and measures biomarkers which are differentially expressed in blood samples of individuals with Pancreatic Cancer (PaC).

  • Genetic biomarkers.
  • Non-invasive test in plasma.
  • Easy, low cost and a common technique for hospitals and laboratories.
  • Confirming Pancreatic cancer diagnosis, identifying benign vs. malign pancreatic cysts to avoid unnecessary surgeries and differential diagnosis between Pancreatic cancer and other pathologies.

PancreaDix® characteristics

Learn more about PancreaDix®

PancreaDix® will typically be prescribed by the Gastroenterologist or the General Practitioner to patients with:

  • Incidental findings in the pancreas
  • Symptoms compatible with pancreatic cancer.
  • Case of chronic pancreatitis or neuroendocrine tumors to confirm that it is not cancer.
  • Case of cysts to diagnose their potential malignancy to proceed with surgery or not.
  • Inconclusive biopsies or images.
  • High-risk for Pancreatic Cancer, recommended for screening (this group of patients should be included in future studies).

PancreaDix® will improve the early detection of premalignant and malignant lesions of pancreatic cancer and it enables physicians to better manage patients with pancreatic cancer and other pancreatic pathologies.

Pancreadix

There are no national or international screening programs for pancreatic cancer. PancreaDix® would also serve as a screening tool for an eligible high-risk population due to hereditary risk or long-standing diabetes.

We are conducting a national clinical study to further validate this technology.

If you want more details, please contact us.

Pancreadix

Amadix